We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
- Authors
van Beers, Erik H.; van Vliet, Martin H.; Kuiper, Rowan; de Best, Leonie; Anderson, Kenneth C.; Chari, Ajai; Jagannath, Sundar; Jakubowiak, Andrzej; Kumar, Shaji K.; Levy, Joan B.; Auclair, Daniel; Lonial, Sagar; Reece, Donna; Richardson, Paul; Siegel, David S.; Stewart, A. Keith; Trudel, Suzanne; Vij, Ravi; Zimmerman, Todd M.; Fonseca, Rafael
- Abstract
<bold>Background: </bold>High risk and low risk multiple myeloma patients follow a very different clinical course as reflected in their PFS and OS. To be clinically useful, methodologies used to identify high and low risk disease must be validated in representative independent clinical data and available so that patients can be managed appropriately. A recent analysis has indicated that SKY92 combined with the International Staging System (ISS) identifies patients with different risk disease with high sensitivity.<bold>Patients and Methods: </bold>Here we computed the performance of eight gene expression based classifiers SKY92, UAMS70, UAMS80, IFM15, Proliferation Index, Centrosome Index, Cancer Testis Antigen and HM19 as well as the combination of SKY92/ISS in an independent cohort of 91 newly diagnosed MM patients.<bold>Results: </bold>The classifiers identified between 9%-21% of patients as high risk, with hazard ratios (HRs) between 1.9 and 8.2.<bold>Conclusion: </bold>Among the eight signatures, SKY92 identified the largest proportion of patients (21%) also with the highest HR (8.2). Our analysis also validated the combination SKY92/ISS for identification of three classes; low risk (42%), intermediate risk (37%) and high risk (21%). Between low risk and high risk classes the HR is >10.
- Subjects
MULTIPLE myeloma diagnosis; GENES; LONGITUDINAL method; MULTIPLE myeloma; PROGNOSIS; TUMOR classification; FLUORESCENCE in situ hybridization; PROPORTIONAL hazards models; GENE expression profiling; KAPLAN-Meier estimator
- Publication
Clinical Lymphoma, Myeloma & Leukemia, 2017, Vol 17, Issue 9, p555
- ISSN
2152-2650
- Publication type
journal article
- DOI
10.1016/j.clml.2017.06.020